Therefore, there is a continued need for the development of novel treatment strategies for MLL-r leukemia, preferentially based on the use of more selective, targeted therapies that are more potent, less toxic and enable the use of lower chemotherapeutic doses for pediatric and infant patients. The gene discussed is KMT2A; the disease is leukemia.